
Applied DNA Receives Approval for TR8™ Pharmacogenomic (PGx) Testing Service from New York State Department of Health
June 13th, 2024
Applied DNA Receives Approval for TR8™ Pharmacogenomic (PGx) Testing Service from New York State Department of Health
June 13th, 2024
Applied DNA Announces Notice of Allowance for U.S. Patent Covering Fundamental Aspect of its Linea™ IVT Platform
June 5th, 2024
Applied DNA Announces Pricing of $12 Million Public Offering
May 28th, 2024
Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA’s Linea DNA™ for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML
May 13th, 2024
Applied DNA Announces Second Quarter Fiscal Year 2024 Financial Results
May 10th, 2024
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement
May 10th, 2024
APDN Awarded Contract by HDT Bio For Rapid Vaccine Development Program
April 25th, 2024
Applied DNA Announces 1-For-20 Reverse Stock Split
April 22nd, 2024
Applied DNA, Alphazyme Agreement for Scale-Up Linea™ RNAP
March 18th, 2024